| RESPIRE repeatability (n = 36) | Clinical testing (n = 400) | Full cohort (n = 3795) |
---|---|---|---|
Demographics | |||
 Age, yr | 49.5 ± 15.9 | 55.4 ± 16.4 | 62.8 ± 15.3 |
 Sex, F/M (F %) | 30/6 (83) | 283/117 (71) | 2355/1440 (62) |
 BSA (m2) | 1.9 ± 0.2 | 1.8 ± 0.2 | 1.8 ± 0.2 |
 WHO FC I, n (%) | 0 (0) | 2 (1) | 47 (1) |
 WHO FC II, n (%) | 2 (6) | 21 (5) | 441 (12) |
 WHO FC III, n (%) | 30 (83) | 338 (85) | 2743 (77) |
 WHO FC IV, n (%) | 4 (11) | 36 (9) | 336 (10) |
Diagnosis, n (%) | |||
 Left Heart Disease | 0 (0) | 0 (0) | 611 (16) |
 Lung Disease | 0 (0) | 0 (0) | 632 (17) |
 CTEPH | 0 (0) | 0 (0) | 728 (19) |
 PAH | 36 (100) | 400 (100) | 1040 (28) |
 Other PAH | 0 (0) | 0 (0) | 84 (2) |
 Other (not PAH) | 0 (0) | 0 (0) | 677 (18) |
Haemodynamics | |||
 mRAP, mmHg | 11 ± 7 | 10.4 ± 6.0 | 10.1 ± 6.0 |
 mPAP, mmHg | 52 ± 13 | 48.0 ± 13.7 | 40.8 ± 14.2 |
 PAWP, mmHg | 10 ± 3 | 10.3 ± 2.9 | 12.8 ± 5.9 |
 Cardiac output L/min | 4.5 ± 1.7 | 4.9 ± 1.5 | 4.9 ± 1.9 |
 Cardiac index, L/min/m2 | 2.5 ± 0.9 | 2.8 ± 0.9 | 2.7 ± 1.0 |
 PVR, dynes/m2 | 899 ± 512 | 720 ± 419 | 562 ± 419 |
 MvO2, % | 65.0 ± 9.1 | 63.5 ± 9.1 | 65.2 ± 9.3 |
CMR volumetric measurements | |||
 RVESVI, ml/m2 | 25.4 ± 9.2 | 46.8 ± 28.2 | 37.3 ± 27.1 |
 RVEDVI, ml/m2 | 63.3 ± 27.6 | 72.7 ± 35.5 | 62.6 ± 35.5 |
 RVSVI, ml/m2 | 37.9 ± 20.7 | 25.9 ± 12.7 | 25.3 ± 15.4 |
 RVEF, % | 43.3 ± 10.0 | 39.1 ± 14.1 | 44.6 ± 16.1 |
CMR area measurements | |||
 Automatic max RA area, cm2 | 22.6 ± 6.3 | 25.5 ± 9.8 | 25.8 ± 10.6 |
 Manual max RA area, cm2 | 22.5 ± 6.3 | 26.0 ± 10.3 | - |
 Automatic min RA area, cm2 | 15.0 ± 5.5 | 18.4 ± 9.4 | 18.5 ± 10.3 |
 Manual min RA area, cm2 | 15.3 ± 5.7 | 19.3 ± 10.1 | - |